T
O he GastrointestinalCancer
ncologist
®
FOLFIRINOXinLocallyAdvancedPancreaticCancer:The
MassachusettsGeneralHospitalCancerCenterExperience
JASONE.FARIS,aLAWRENCES.BLASZKOWSKY,aSHAUNAGHMCDERMOTT,cALEXANDERR.GUIMARAES,cJACKIESZYMONIFKA,d
MAIANHHUYNH,bCRISTINAR.FERRONE,eJENNIFERA.WARGO,fJILLN.ALLEN,aLAURENE.DIAS,gEUNICEL.KWAK,aKEITHD.LILLEMOE,e
SARAHP.THAYER,eJANETE.MURPHY,aANDREWX.ZHU,aDUSHYANTV.SAHANI,cJENNIFERY.WO,bJEFFREYW.CLARK,a
CARLOSFERNANDEZ-DELCASTILLO,dDAVIDP.RYAN,aTHEODORES.HONGb
aDepartmentofHematology/Oncology,bDepartmentofRadiationOncology,cDepartmentofRadiology,dBiostatisticsCenter,
eDepartmentofGeneralandGastrointestinalSurgery,andfDepartmentofSurgicalOncology,MassachusettsGeneralHospital,Boston,
Massachusetts;gDepartmentofHematologyOncology,NorthShoreCancerCenter,Danvers,Massachusetts
Disclosuresofpotentialconflictsofinterestmaybefoundattheendofthisarticle.
KeyWords. FOLFIRINOX • Locallyadvancedpancreaticcancer • Neoadjuvant • R0resection • Chemoradiation
ABSTRACT
Theobjectiveofourretrospectiveinstitutionalexperienceisto gression-freesurvivalwas11.7months.Fiveof22patients
reporttheoverallresponserate,R0resectionrate,progression- wereabletoundergoR0resectionsfollowingneoadjuvant
freesurvival,andsafety/toxicityofneoadjuvantFOLFIRINOX(5- FOLFIRINOXandchemoradiation.Threeofthefivepatients
fluorouracil[5-FU],oxaliplatin,irinotecan,andleucovorin)and haveexperienceddistantrecurrencewithin5months.Thirty-
chemoradiationinpatientswithlocallyadvancedpancreatic twopercentofpatientsrequiredatleastoneemergencyde-
cancer(LAPC).PatientswithLAPCtreatedwithFOLFIRINOX partment visit or hospitalization while being treated with
wereidentifiedviatheMassachusettsGeneralHospitalCan- FOLFIRINOX.FOLFIRINOXpossessessubstantialactivityinpa-
cerCenterpharmacydatabase.Demographicinformation, tientswithLAPC.TheuseofFOLFIRINOXwasassociatedwith
clinicalcharacteristics,andsafety/tolerabilitydatawerecom- conversiontoresectabilityin(cid:1)20%ofpatients.However,the
piled.Formalradiographicreviewwasperformedtodeter- recurrencesfollowingR0resectioninthreeoffivepatients
mineoverallresponserates(ORRs).Twenty-twopatientswith andthetoxicitiesobservedwiththeuseofthisregimenraise
LAPCbegantreatmentwithFOLFIRINOXbetweenJuly2010 importantquestionsabouthowtobesttreatpatientswith
andFebruary2012.TheORRwas27.3%,andthemedianpro- LAPC.TheOncologist2013;18:543–548
ImplicationsforPractice:Theprognosisforpatientswithlocallyadvancedpancreaticcancer,whoconstituteaboutalmostathird
ofpatientspresentingwithanewdiagnosisofpancreaticcancer,isquitepoor,withamediansurvivalofapproximately1year.The
idealtreatmentparadigmforthesepatientsisunclear,butbasedontheexperiencewithFOLFIRINOXinthemetastaticsetting,
multipleinstitutionshavebeguntotreatwithFOLFIRINOXforpatientswithlocallyadvanceddisease.Inthispaper,wedescribe
ourinstitutionalexperiencewithFOLFIRINOXfollowedbychemoradiationinpatientswithlocallyadvancedpancreaticcancer.
Weprovideevidenceforsubstantialactivity,withconversiontosurgicalresectabilityinmorethan20%ofpatients.Webelievethatfur-
therstudyiswarrantedonthispromisingtreatmentapproachforpatientswithlocallyadvancedpancreaticcancer.
INTRODUCTION
Pancreaticcancerisestimatedtohaveaffectedover43,000 clear,withnodefinitiveguidancefromstudiestodateonthe
patients and to have caused 37,000 deaths in the United superiority of chemotherapy versus chemoradiation ap-
Statesin2012[1].Only10%–20%ofpatientspresentwithsur- proaches.Withregardtogemcitabinealoneversusgemcitabine-
gicallyresectabledisease,andforpatientswhoundergosur- based chemoradiation, two recent randomized controlled
gicalresection,the5-yearoverallsurvivalrateis15–20%. studiesreacheddifferentconclusions.TheFederationFranco-
Approximately30%ofpatientspresentingwithanewdiagno- phonedeCancerologieDigestiveandSocieteFrancophonede
sisofpancreaticcancerlackevidenceofsystemicmetastases Radiotherapie Oncologique trial demonstrated improved
andpresentwithlocallyadvanceddisease[2,3],forwhichme- overallsurvivalwithgemcitabinealonecomparedwithinduc-
dianoverallsurvivalisapproximately1year. tionchemoradiationfollowedbygemcitabinechemoradia-
Theoptimaltreatmentparadigmandtheroleforchemora- tionemploying5-FU/cisplatin[4].Incontrast,theEastern
diationforpatientswithlocallyadvancedpancreaticcancerisun- CooperativeOncologyGroup4201trialcomparedgemcit-
Correspondence:JasonE.Faris,M.D.,MassachusettsGeneralHospitalCancerCenter,Yawkey7E,55FruitStreet,Boston,Massachusetts02114,USA.
Telephone:617-724-4000;Fax:617-726-0452;E-Mail:jfaris@partners.org ReceivedNovember11,2012;acceptedforpublicationApril4,2013;
firstpublishedonlineinTheOncologistExpressonMay8,2013.©AlphaMedPress1083-7159/2013/$20.00/0http://dx.doi.org/10.1634/
theoncologist.2012-0435
TheOncologist2013;18:543–548 www.TheOncologist.com ©AlphaMedPress2013
544 FOLFIRINOXinLocallyAdvancedPancreaticCancer
abinealonewithgemcitabine-basedchemoradiation,with Table1. Demographicandclinicalcharacteristics(n(cid:2)22)
improvedoverallsurvivalwiththechemoradiationarm(one-
Characteristic n(%)
sidedp(cid:2).017),whichwasaccompaniedbysubstantialin-
Sex
creasesingrade4/5toxicities[5].Bothstudiesdidnotaccrue
toplannedpatientenrollment,hamperingtheinterpretation Male 13
ofresults.Therehavebeennorandomizedtrialstoassessthe Female 9
potentialbenefitofinitialchemotherapyfollowedbychemo- MedianageatFOLFIRINOX(range) 63(45–78)
radiation,althoughretrospectivedatasupportthisapproach Weightloss(lb)atpresentation 18(82%)
[6,7].Inaddition,somepatientswithlocallyadvancedpancre-
Historyofsmoking
aticcancerwillberenderedresectablebyvirtueofhavingan
Never 13(59%)
excellentresponsetotherapy[8–10].
Formerorcurrent 9(41%)
Thelandscapeforsystemictherapyformetastaticpan-
creatic cancer has changed significantly with the use of Historyofdiabetespriortodiagnosis 6(27%)
FOLFIRINOX(5-fluorouracil[5-FU],oxaliplatin,irinotecan, Historyofpancreatitis 3(14%)
andleucovorin).InarandomizedphaseIIIstudycomparing PresenceofstentpriortoFOLFIRINOX 10(45%)
FOLFIRINOXwithgemcitabinein342chemotherapy-naivepa- Priorchemotherapyregimens
tientswithmetastaticpancreaticcancer,FOLFIRINOXwasas-
0 21(95%)
sociatedwithanimprovedsurvival,progression-freesurvival,
1 0
andresponserate.[11].Basedonthedatasupportingtheuse
(cid:1)2 1(5%)
ofFOLFIRINOXinthemetastaticsetting,thereisgreatinterest
ECOGperformancestatus
inassessingtheactivityofFOLFIRINOXforpatientswithlocally
advanced pancreatic cancer. Two important unanswered 0 12(55%)
questionsare(a)willthebenefitinresponserateandoverall 1 8(36%)
survivalinthemetastaticsettingtranslatetopatientswithlo- Notrecorded 2(9%)
callyadvancedpancreaticcancer?and(b)arecurative-intent Locationofprimarymass
resectionspossibleinpatientswhorespondtotreatment?In
Head/uncinate 14(64%)
thisreport,wepresentourinstitutionalexperienceinpatients
Tail 8(36%)
withexclusivelylocallyadvancedpancreaticcancertreated
MedianCA19–9atpresentation 457((cid:3)1to3,630)
withFOLFIRINOX.
MedianCEAatpresentation(n(cid:2)17) 1.8(1–10)
Baselinelaboratoryvalues
METHODS
Creatinine 0.81
Allpatientswithadiagnosisoflocallyadvancedpancreatic
cancer(LAPC)whobegantreatmentwithFOLFIRINOXatthe Alaninetransaminase 28.5
MassachusettsGeneralHospital(MGH)CancerCenterbe- Aspartatetransaminase 21
tweenJuly2010andFebruary2012wereidentifiedbysearch- Totalbilirubin 0.45
ingthecancercenterpharmacydatabaseunderaminimalrisk Whitebloodcells 6.9
studyapprovedbytheinstitutionalreviewboard.MGHisa
Hematocrit 38.6
NationalComprehensiveCancerNetwork(NCCN)-designated
Platelets 209
institutionandfollowstheNCCNdefinitionofunresectable,
whichincludesthosewithdistantmetastases,metastasesto Abbreviation:ECOG,EasternCooperativeOncologyGroup;CA19–9,
carbohydrateantigen19–9;CEA,carcinoembryonicantigen.
lymphnodesbeyondtheresectionfield,andthenvariesac-
cordingtodiseaselocationinthehead,body,ortailofthepan-
creas,butincluding(cid:1)180degreeencasementofthesuperior Neoadjuvant chemotherapy consisted of four cycles of
mesentericartery,unreconstructablesuperiormesenteric FOLFIRINOX,followedbyrepeatcomputedtomography(CT)
veinorportalveinocclusion,aorticinvasion,orceliacencase- imaging.Ifstablediseaseorbetterwasobservedcompared
ment[12]. withbaseline,anadditionalfourcyclesofFOLFIRINOXwas
Forthosepatientsreceivingfull-doseFOLFIRINOX,dosing planned.IfrepeatCTimagingagainrevealedstablediseaseor
wasasperthephaseIIItrialofFOLFIRINOX[11],with5-FUad- better,allpatientswererecommendedtoundergochemora-
ministeredasabolusof400mg/m2,bolusleucovorin400mg/ diation.Forallpatients,treatmentwascontinueduntildis-
m2,followedbycontinuousinfusionat1200mg/m2perday easeprogression,patientpreference,orlimitingtoxicities.For
for46hours,oxaliplatin85mg/m2,andirinotecan180mg/m2. patients receiving chemoradiation following neoadjuvant
Prophylacticpegfilgrastimwasadministeredtoallpatients24 FOLFIRINOX,aradiosensitizingchemotherapy,suchascontin-
hoursafterthe46-hourinfusioninallcyclescontaining5-FU, uousinfusion5-FUorcapecitabine,wasemployedalongwith
oxaliplatin,andirinotecan.Althoughbasedonclinicalstatus intensity-modulatedradiationtherapydeliveredto50.4Gyin
andorganfunctionatthetimeofstartingFOLFIRINOX,choices 28fractions.Multidisciplinaryreviewwithradiology,surgery,
regardingdosingmodificationsweredeterminedbytheindi- radiationoncology,andmedicaloncologywasperformedfor
vidualtreatingoncologist.Ifoneofthesethreedrugswas baselinescansandforscansfollowingcompletionofchemo-
omitted,pegfilgrastimwasadministeredatthediscretionof radiationtreatment.
thetreatingphysician.Theapproachforallpatientsincluded Demographicinformation,clinicalcharacteristics,safety/
neoadjuvantchemotherapy,followedbychemoradiation. tolerabilityasmeasuredbygradabletoxicities,andemer-
©AlphaMedPress2013
Faris,Blaszkowsky,McDermottetal. 545
gencydepartmentvisits(orhospitalizations)weretabulated. Table2. Treatment:FOLFIRINOXandchemoradiation
Formalradiographicreviewwasretrospectivelyperformedto
Characteristic n
determineoverallresponserates(ORRs).Patientswereas-
Mediannumberofcycles 8
sessedfortumorresponseaccordingtotheResponseEvalua-
tionCriteriainSolidTumorsguidelines(RECIST,version1.1) Mediannumberofcycleswith5-FU,oxaliplatin, 7.5
irinotecan
[13].Theimageswereconsensus-readbytworadiologists,
with6and15yearsexperience.Wecomparedmeasurable Mediannumberofcycleswithfull-dose 2.5
FOLFIRINOX
targetlesions(TLs),whicharedefinedassoft-tissuelesions
No.ofpatientsstartingwith5-FU,oxaliplatin, 17
thatcouldbeaccuratelymeasuredinatleastonedimension,
irinotecan
withthelargestdiameterbeingatleast1cmoratleast1.5cm
No.ofpatientsomittingirinotecanwithfirst 5
intheshortaxisforlymphnodes.Progressivedisease(PD)was
cycle
consideredwhentherewasatleasta20%increaseinthesum
No.ofpatientscompletingatleast2full-dose 12
ofthetotalsizeofTLsorthepresenceofanewunequivocal
FOLFIRINOXcycles
metastaticdisease,partialresponse(PR)whentherewasat
No.ofpatientscompletingatleast4full-dose 9
leasta30%decreaseinthetotalsizeofTLs,andstabledisease FOLFIRINOXcycles
(SD)whentherewasanypercentchangebetween(cid:4)19%and
No.ofpatientscompletingatleast6full-dose 3
(cid:5)29%inthesumofthetotalsizeofTLs.Progression-freesur-
FOLFIRINOXcycles
vival(PFS)wascalculatedfromthedateofFOLFIRINOXtothe No.ofpatientscompletingatleast8full-dose 1
earliestofthefollowing:dateofradiographicprogression(lo- FOLFIRINOXcycles
calormetastatic),appearanceofmetastaticdiseaseatsurgi- No.ofpatientsreceivingradiationafter 20
cal exploration, or death. Patients without radiographic FOLFIRINOX
progressionwerecensoredatthetimeoflastradiographs.PFS 5-FU/capecitabineasradiosensitizer 18
estimateswereobtainedusingtheKaplan-Meiermethod,and 5-FU/capecitabine(cid:4)other 2
Greenwood’sformulawasusedtoobtaintwo-sided95%con-
Mediannumberoffractions(range) 28(28–30)
fidence intervals. All patients receiving FOLFIRINOX were
Totaldosedelivered,Gy(range) 50.4(45–54)
eligiblefortoxicityanalysis.Descriptivestatisticswereem-
ployedtosummarizedatafromtheaboveanalyses.
Table3. Objectiveresponserate
RESULTS No.of Point 95%
patients estimate confidence
Twenty-twopatientswithlocallyadvancedpancreaticcancer Responselevel (n(cid:1)22) (%) interval
receivedFOLFIRINOXattheMGHCancerCenterinthe20-
Completeresponse 0 0.0 NA
monthperiodspanningJuly2010toFebruary2012.Baseline
demographicandclinicalcharacteristicsarelistedinTable1. Partialresponse 6 27.3 (10.7–50.2)
Themedianageofpatientswas63years(range:49–78years), Stabledisease 16 72.7 (49.8–89.3)
including13menand9women.Allpatientsexceptonewere Progressivedisease 0 0.0 NA
chemotherapyna¨ive.Fifty-eightpercentofpatientshadpan-
Abbreviation:NA,notavailable.
creatichead/uncinatelesionsand42%hadbody/taillesions.
Tenofthe22patientshadabiliarystentinplaceatthestartof
FOLFIRINOX.Allpatientswitharecordedstatusinclinicnotes Overall,sixnonconfirmedpartialresponses(PR)wereobserved
hadanEasternCooperativeOncologyGroupperformance in22evaluablepatients(ORR27.3%)whileonFOLFIRINOX(Table
status of 0 or 1. Median follow-up for patients was 19.3 3).Oneadditionalpatienthadanonconfirmedpartialresponse
months. followingchemoradiation,andanotherhadanonconfirmed
Atotalof178cyclesofchemotherapyweregiventothe22 partialresponsefollowingchemoradiationandintraoperative
patients,ofwhich156cyclescontainedallthreeactivedrugs IORT,foratotalof8of22evaluablepatients(ORR36.4%).In
(5-FU,irinotecan,andoxaliplatin).Sixty-sixcycleswerewith all,19of22patientshaddecreasesinCA19–9by30%ormore,
full doses of FOLFIRINOX. Five patients were started on and17ofthe22haddecreasesof50%ormorefrombaseline
FOLFOXduringtheinitialcycle(s)ofchemotherapy,withaddi- CA19–9priortostartingFOLFIRINOX.Atotalof13of22pa-
tionofirinotecantolatercycles.Anadditionalfivepatients tientshad(cid:1)20%reductionsintargetlesionmeasurementsas
werestartedonFOLFIRINOX,witheventualdiscontinuationof indicatedbythewaterfallplotinFigure1.Followingneoadju-
oxaliplatinoririnotecan.Patientsreceivedamedianof8cy- vantFOLFIRINOX,12patientsweretakentotheoperating
clesofFOLFIRINOX,and7.5cyclesinwhichallthreeactive roomforexploration.FivepatientsunderwentR0resections
drugswereincluded(Table2).Patientsreceivedamedianof (Fig.2),ofwhomonepatienthadnoremainingevidenceoftu-
2.5full-doseFOLFIRINOXcycles.Ofthe17patientswhore- mor.Sevenpatientshadsurgicallyunresectablediseaseand
ceived5-FU,irinotecan,andoxaliplatinonthefirstcycle,13 sixofthesepatientshadintraoperativeradiationtherapy
receivedfulldosesofeachdrug,includingthe5-FUbolusof (IORT)administered,withorwithoutpalliativehepaticojeju-
400mg/m2.FollowingFOLFIRINOX,allbuttwopatientsre- nostomyand/orgastrojejunostomy;ofthesixundergoing
ceivedfluoropyrimidine-basedchemoradiation(Table2).In IORT,onlyonepatienthasexperiencedprogressivedisease.
thefivepatientsundergoingsurgicalresections,amedianof8 OurdecisiontoproceedwithIORTwasbasedontheexperi-
cyclesofFOLFIRINOXweredelivered(range6–8),withame- enceofWillettetal.[14],inwhichtheretrospectiveexperi-
dianof4full-dosecyclesofFOLFIRINOX(range3–8). encewithIORTforunresectablepancreaticcanceratMGH
www.TheOncologist.com ©AlphaMedPress2013
DISCUSSION
Thisisthelargestpublishedseriesofpatientswithlocallyad-
vancedpancreaticcancertreatedwithFOLFIRINOX.Recently,
theactivityofFOLFIRINOXinpatientswithborderlineorlo-
callyadvancedpancreaticcancerwasreported[15],whichin-
cludedatotalof18patients,ofwhom14hadlocallyadvanced
disease.Inthese14patients,fourpatientsproceededdirectly
tosurgeryafter3–12cyclesofFOLFIRINOX,andtwoofthese
14hadanR0resection.Anadditionalthreepatientsunder-
wentR0resectionsaftercompletingchemoradiationtreat-
ment.Thus,theR0resectionrateinthiscaseseries,excluding
wascharacterized.The3-yearsurvivalwas7%,withfivepa-
thepatientswithborderlineresectabledisease,was36%(5of
tientssurvivingmorethan5years.
14patients).OurR0resectionrateof23%(5of22patients)is
OnepatientdidnotreceiveIORTduetothediscoveryof
intherangereportedbyHoseinetal.[15]andmayreflecta
peritonealandomentalimplants.Ofthefivepatientswhohad
neweraofconvertinglocallyadvancedpancreaticcancerinto
R0resections,threehaveexperienceddistantrecurrence,ata
resectablepancreaticcancerwiththeuseofFOLFIRINOX.
medianof81days(range:74–144days).Onepatientisnow
GiventhesuperioractivityofFOLFIRINOXincomparison
morethan500dayssinceresectionandhasnoevidenceof
withgemcitabine,itisextremelyimportanttoestablishthe
recurrence.Medianprogression-freesurvivalfortheentire
activityandtoxicityofFOLFIRINOXinpatientswithlocallyad-
cohortwas11.7months(95%confidenceinterval:8.3–21.8
vancedpancreaticcancer.Ourexperienceraisesatleastfour
months;Fig.2),with14ofthe22patientsdemonstratinglo-
importantissues.Thefirstmajorissueinvolvesthesubjective
calordistantprogressionthusfar.Overallsurvivalwasnot
definitionoflocallyadvancedandborderlinepancreaticcan-
calculatedbecauseonlyfivepatientshavediedsincestart-
cer.TheR0resectionratesrangefrom8%–64%in510pa-
ingFOLFIRINOX.
tients from 13 studies employing various neoadjuvant
Withregardtotolerability,onlyeventsthatcouldbecap-
chemoradiationprotocolsforunresectablepancreaticcancer
turedandappropriatelygradedfromthemedicalrecordwere
[16].DespitethelargediscrepancyinR0resectionrates,over-
included(Table4).Atotalof7ofthe22(32%)requiredhospi-
allsurvivalissimilarbetweenthestudies,suggestingthatthe
talizationoremergencydepartmentvisitsduringFOLFIRINOX,
extremeheterogeneityinresectionratesobservedinthis
(cid:1)50%ofwhichwerefornon-neutropenicfeversordehydra-
meta-analysisisduemoretothesubjectivedefinitionofbor-
tion/diarrhea.Becausethreepatientswereadmittedmultiple
derlineandlocallyadvanceddisease.Ourseriesisrestrictedto
times,therewere12hospitalizationevents.Althoughthere patientswithlocallyadvancedpancreaticcancerasdeter-
werefourpatientswhodevelopedgrade3or4neutropenia, minedbyanexperiencedpancreaticsurgerygroup.Itiscritical
therewerenocasesoffebrileneutropenia.Onlytwopatients thatfuturestudiesseparatepatientswithlocallyadvanced
discontinuedFOLFIRINOXfortoxicitiesrelatedtotreatment. andborderlineresectabledisease.Inadditiontoevaluating
InthefivepatientswhounderwentR0resections,themedian thesetwocategoriesseparately,establishingformalconsen-
lengthofstaywas7days(range5–35).Twoofthefivepatients suscriteriaforlocallyadvancedandborderlinediseaseisof
hadnopostsurgicalcomplications.Twopatientshadpostop- criticalimportance.Atpresent,oneinstitution’slocallyad-
erativeinfections.Onepatientwasreadmitted10daysafter vancedpancreaticcancermaybeconsideredaborderlinere-
dischargewithfeversandleukocytosis,althoughculturesand sectablepatientinanotherinstitution.Theunevendefinition
workupwasnegative.Oneofthepatientswhohadapostop- andapplicationofcriteriausedtoassigncategoriestothera-
erativeinfectionalsohadtoundergopermanenttranshepatic diographicpresentationofpatientswithpancreaticcancer
drainplacementduetomultiplebiliarystricturesafterneoad- probablyintroducesthegreatestamountofvariabilityinthe
juvantFOLFIRINOXandchemoradiation(transhepaticdrains percentageofpatientswhocanundergoapotentialcurative
placedduringWhipplesurgery). resection.Therearecriteriatodefinelocallyadvancedand
0.1
8.0
6.0
4.0
2.0
0.0
FOLFIRINOX progression-free survival
Months from start of FOLFIRINOX
ytilibaborp
lavivruS
546 FOLFIRINOXinLocallyAdvancedPancreaticCancer
Figure2. Waterfallplotofmaximumpercentchangefrombase-
linescansduringFOLFIRINOXtreatment.
0 6 12 18 24
Time Point estimate 95% confidence interval
6 months 90.9% (68.3%, 97.6%)
9 months 67.3% (43.2%, 82.9%)
12 months 44.8% (22.5%, 65.0%)
15 months 29.9% (10.5%, 52.4%)
Figure1. Progression-freesurvival.
©AlphaMedPress2013
Faris,Blaszkowsky,McDermottetal. 547
Table4. Hospitalizationandselectedtoxicities Third,itiscriticaltoassessthetolerabilityofFOLFIRINOX
specificallyinpatientswithlocallyadvanceddiseasewhoof-
HospitalizationsorEDvisitsduringFOLFIRINOX 12
tenhavecompromisedbiliarydrainagepriortoembarkingon
Biliaryobstruction/cholangitis 1
amulti-institutionalstudy.Withmorethan30%ofpatientsre-
Diarrhea/dehydration 4
quiringanemergencydepartmentvisitoradmissionduring
Fevers(nonneutropenic,nonbacteremic) 3 FOLFIRINOXtreatment,thisregimenisquitetoxicinapatient
Nonneutropenicbacteremia 2 populationthatisconsideredtechnicallyincurable.Althougha
Oxaliplatindesensitization 1 thirdofthesehospitalizationswerebriefadmissionsfordiar-
Pulmonaryembolism 1 rhea/dehydration,thereweretwoadmissionsfornon-neutro-
penicbacteremia.Reassuringly,withtheuseofprophylactic
Neutropenia 6
growthfactorwithallcyclesofFOLFIRINOXinthisseries,there
Grade1 0
werenocasesoffebrileneutropenia.Givenourexperience,
Grade2 2
upfrontdosemodificationoftheFOLFIRINOXregimenmight
Grade3 3
benecessary,particularlyinlesswell-selectedpopulationsof
Grade4 1 patients.Currently,theimpactondosereductions,suchas
Febrileneutropenia 0 eliminationofthe5-FUbolus,isunknown,bothintermsofef-
Anemia 22(100%) ficacyandtoxicity.Thereasonforthelargediscrepancyinfull-
Grade1or2 22 doseFOLFIRINOXcyclesinourstudy(37%ofcycles)andthe
Hoseinetal.study(83%ofcycles)[15]isunknown,butitmay
Thrombocytopenia 18
relatetodifferencesinpatientselection,includingageand
Grade1 16
performancestatus.Inaddition,approximatelyone-thirdof
Grade2 1
patientshadborderlinediseaseintheHoseinetal.study,
Grade3 1
whereasallpatientsinourstudyhadlocallyadvanceddisease.
Thromboembolicevents 1 Alimitationofthisretrospectiveanalysisisthatwecannotac-
ElevatedALT/AST 16 curatelygradesubjectivecomplaintssuchasperipheralneu-
Grade1 11 ropathy, fatigue, and diarrhea from the medical record.
Grade2 3 Retrospectivedataonsubjectivetoxicitiesisinherentlyin-
complete and unreliable and, thus, was not included. Al-
Grade3 2
thoughofclearimportancetoadiscussionoftolerabilityofa
Abbreviations:ALT,alaninetransaminase;AST,aspartate
newerchemotherapyregimensuchasFOLFIRINOX,anaccu-
transaminase;ED,emergencydepartment.
rateassessmentofthefrequencyandseverityofthesesideef-
fectsmustbeassessedprospectively.
Afinalandmorebasicquestioniswhetherapatientwith
borderline pancreatic cancer, which are defined by NCCN initiallyunresectablediseasewhoachievesanR0resectionaf-
guidelines specifically by location in the pancreatic head, terneoadjuvantFOLFIRINOXisreallycurable.Wouldpalliative
body,ortail[12].Asofyet,however,therehasnotbeencom- systemicchemotherapyand/orchemoradiationachievethe
pleteacceptanceofandadoptionofthesecriteria.AtMGH, sameoutcome,avoidingtheknownmorbidityandpotential
wehaveamultidisciplinarymeetingwithradiology,surgery, mortalityofsurgicalresection?Inourseries,threeofthefive
radiationoncology,andmedicaloncology,duringwhichthe patientswithanR0resectiondevelopeddistancerecurrence
imaging,consistingofapancreatic-protocolCT,isreviewedin atamedianof81daysaftersurgery.Althoughwesharethe
detailtoassignastagebasedonNCCNcriteria.Amajorcriti- enthusiasmthatneoadjuvanttherapymaypermitresection
cismofthecurrentstudyisthelackofanindependentreview forpatientswithinitiallyunresectabledisease,theseearlyre-
boardassessingouradherencetothesecriteria. sultsremindusthatthevastmajorityofpatientswithpancre-
Asecondimportantissueinvolvesthecontributionand aticcancerhavesystemicdisease.
sequencing of chemoradiation following neoadjuvant Investigationofbiomarkersthatmayallowforprediction
FOLFIRINOX.Inourstudy,withtheexceptionofonepatient oflocalversussystemicrecurrencecouldprovehelpfulinde-
withprogressivediseaseandanotherwhodeclinedchemo- cisionsregardingchemoradiationforthesepatients.Forex-
radiation,allpatientsproceededtochemoradiationafter ample,anautopsyseriesfoundastrongassociationbetween
FOLFIRINOX.IntheHoseinetal.study[15],asubsetofpa- localrecurrenceandanintactDPC4gene[17].Ifthisfindingis
tients were brought directly to the operating room for corroboratedinotherlargerstudies,chemoradiationcouldbe
attemptedresectionfollowingmaximalresponsetoFOL- reservedforpatientswithintactDPC4.Searchingforadditional
FIRINOX;interestingly,onlyhalfofthesepatients(twooffour biomarkersthatmightallowforpredictionofresponsetoand
patients)wereabletohaveR0resections.Althoughchemora- toxicityfromFOLFIRINOX,aswellasbenefitfromchemoradia-
diationmayultimatelyproveessentialforR0resections,crit- tion,wouldbehelpfulinpersonalizingtherapieswithamplepo-
ics argue that this window of time could allow for tentialtobothimproveresponseandreduceharm.
micrometastaticdisease,previouslycontrolledviaFOLFIRI- Our institutional experience with FOLFIRINOX should
NOX,todevelop.Importantly,ourexperiencesuggeststhat serveasatemplateforfutureclinicaltrialsdesignedtodefini-
thisisanuncommonevent.Thetimingandsequencingofneo- tivelyaddresstheutilityofFOLFIRINOXforpatientswithboth
adjuvantchemotherapyandchemoradiationisanactivede- locallyadvancedandborderlineresectablepancreaticcancer.
bateatallcooperativegroupmeetings. Currently,wehaveseparateprotocolsatourinstitutionfor
www.TheOncologist.com ©AlphaMedPress2013
548 FOLFIRINOXinLocallyAdvancedPancreaticCancer
patientswithclearlyresectabledisease,borderlineresectable Provisionofstudymaterialsorpatients:TheodoreHong
disease,andlocallyadvanceddisease.Theissuesregardingin- Collectionand/orassemblyofdata:JasonFaris,ShaunaghMcDermott,Alex
Guimaraes,MaiAnhHuynh,DavidRyan,TheodoreHong
tegrationofFOLFIRINOXintothesedifferentstagesofdisease
Dataanalysisandinterpretation:JasonFaris,ShaunaghMcDermott,Alexan-
arecriticallyimportantinthepancreaticcancercommunity. derGuimaraes,JackieSzymonifka,MaiAnhHuyng,TheodoreHong,David
Ryan,LawrenceBlaszkowsky
CONCLUSION Manuscriptwriting:JasonFaris,LawrenceBlaszkowsky,ShaunaghMcDer-
For patients with locally advanced pancreatic cancer, mott,AlexanderGuimaraes,JackieSzymonifka,MaiAnhHuynh,Cristina
Ferrone,JenniferWargo,JillAllen,LaurenDias,EuniceKwak,KeithLillemoe,
FOLFIRINOXpossessessubstantialactivity,anditsusewasas-
SarahThayer,JanetMurphy,AndrewZhu,DushyantSahani,JenniferWo,
sociatedwithconversiontoresectablestatusinmorethan JeffreyW.Clark,CarlosFernandez-DelCastillo,DavidRyan,TheodoreHong
20%ofpatients.However,recurrentdiseasewasdiscovered
Finalapprovalofmanuscript:JasonFaris,LawrenceBlaszkowsky,Shaunagh
inthreeofthefivepatients.Therewasasignificanttoxicitysig- McDermott,AlexanderGuimaraes,JackieSzymonifka,MaiAnhHuynh,Cris-
nal,withnearlyathirdofpatientsrequiringatleastoneemer- tinaFerrone,JenniferWargo,JillAllen,LaurenDias,EuniceKwak,KeithLil-
lemoe,SarahThayer,JanetMurphy,AndrewZhu,DushyantSahani,Jennifer
gency department visit or hospitalization. The optimal
Wo,JeffreyW.Clark,CarlosFernandez-DelCastillo,DavidRyan,Theodore
strategyfortreatingpatientswithlocallyadvancedpancreatic Hong
cancerrequiresfurtherstudy.
DISCLOSURES
ACKNOWLEDGMENTS JasonFaris:N-of-One(C/A);Roche(RF);AlexanderGuimaraes:
ThesedatawerepresentedinpartattheASCOGastrointesti- SiemensMedical(C/A);AndrewZhu:SanofiAventis,Eisai,Exelixia,
nalCancerSymposium2012,SanFrancisco,California. DaiichiSankyo(C/A);BayerOnyx,Lilly(RF);TheodoreHong:Illumina
(C/A);Novartis(RF).Theotherauthorsreportednofinancial
relationships.
AUTHORCONTRIBUTIONS
C/A:Consulting/advisoryrelationship;RF:Researchfunding;E:Employment;H:Honorariareceived;
Conception/Design:JasonFaris,TheodoreHong,LawrenceBlaszkowsky,Jef- OI:Ownershipinterests;IP:Intellectualpropertyrights/inventor/patentholder;SAB:scientific
freyClark,DavidRyan advisoryboard
REFERENCES
1.SiegelR,NaishadhamD,JemalA.Cancerstatis- 7.KrishnanS,RanaV,JanjanNAetal.Induction 13.EisenhauerEA,TherasseP,BogaertsJetal.
tics,2012.CACancerJClin2012;62:10–29. chemotherapy selects patients with locally ad- Newresponseevaluationcriteriainsolidtumours:
2.PhilipPA.Locallyadvancedpancreaticcancer: vanced,unresectablepancreaticcancerforoptimal RevisedRECISTguideline(version1.1).EurJCancer
Whereshouldwegofromhere?JClinOncol2011; benefitfromconsolidativechemoradiationther- 2009;45:228–247.
29:4066–4068. apy.Cancer2007;110:47–55. 14.WillettCG,DelCastilloCF,ShihHAetal.
3.VincentA,HermanJ,SchulickRetal.Pancreatic 8.HuguetF,GirardN,GuercheCSetal.Chemora- Long-term results of intraoperative electron
cancer.Lancet2011;378:607–620. diotherapyinthemanagementoflocallyadvanced beamirradiation(IOERT)forpatientswithunre-
pancreaticcarcinoma:Aqualitativesystematicre- sectablepancreaticcancer.AnnSurg2005;241:
4.ChauffertB,MornexF,BonnetainFetal.PhaseIII view.JClinOncol2009;27:2269–2277. 295–299.
trialcomparingintensiveinductionchemoradiother-
apy(60Gy,infusional5-FUandintermittentcisplatin) 9.ArvoldND,RyanDP,NiemierkoAetal.Long-term 15.HoseinPJ,MacintyreJ,KawamuraCetal.Aret-
followedbymaintenancegemcitabinewithgemcit- outcomes of neoadjuvant chemotherapy before rospectivestudyofneoadjuvantFOLFIRINOXinunre-
abinealoneforlocallyadvancedunresectablepancre- chemoradiationforlocallyadvancedpancreaticcan- sectableorborderline-resectablelocallyadvanced
aticcancer.Definitiveresultsofthe2000–01FFCD/ cer.Cancer2012;118:3026–3035. pancreaticadenocarcinoma.BMCCancer2012;12:
SFROstudy.AnnOncol2008;19:1592–1599. 10.HabermehlD,KesselK,WelzelTetal.Neoad- 199.
5.LoehrerPJSr.,FengY,CardenesHetal.Gemcit- juvantchemoradiationwithgemcitabineforlocally 16.MorgantiAG,MassaccesiM,LaTorreGetal.A
abinealoneversusgemcitabineplusradiotherapy advancedpancreaticcancer.RadOncol2012;7:28. systematicreviewofresectabilityandsurvivalafter
inpatientswithlocallyadvancedpancreaticcancer: 11.ConroyT,DesseigneF,YchouMetal.FOLFIRI- concurrentchemoradiationinprimarilyunresect-
AnEasternCooperativeOncologyGrouptrial.JClin NOXversusgemcitabineformetastaticpancreatic ablepancreaticcancer.AnnSurgOncol2010;17:
Oncol2011;29:4105–4112. cancer.NEnglJMed2011;364:1817–1825. 194–205.
6.HuguetF,AndreT,HammelPetal.Impactof 12.NationalComprehensiveCancerNetwork. 17.Iacobuzio-DonahueCA,FuB,YachidaSetal.
chemoradiotherapyafterdiseasecontrolwithche- NCCNclinicalpracticeguidelinesinoncology;ver- DPC4genestatusoftheprimarycarcinomacorre-
motherapyinlocallyadvancedpancreaticadeno- sion2.2012.Availableathttp://www.nccn.org// lateswithpatternsoffailureinpatientswith
carcinomainGERCORphaseIIandIIIstudies.JClin professionals/physician_gls/pdf/pancreatic.pdf. pancreaticcancer.JClinOncol2009;27:1806–
Oncol2007;25:326–331. AccessedApril16,2013. 1813.
EDITOR’SNOTE:Seetheaccompanyingcommentaryonpages487–489ofthisissue.
©AlphaMedPress2013
